Integrating Oral THC:CBD Into Chronic Neuropathic Pain Management in Primary Care: A Two-Patient Observational Case Series

Authors

• Camryn Butera, Philadelphia College of Osteopathic MedicineFollow
• Tytianna Robinson, Philadelphia College of Osteopathic MedicineFollow
• Samantha Temucin, Philadelphia College of Osteopathic MedicineFollow
• Jade McNulty, Philadelphia College of Osteopathic MedicineFollow
• Ryan Pinto, Philadelphia College of Osteopathic MedicineFollow
• Maya Rakoczy, Philadelphia College of Osteopathic MedicineFollow
• Jessica Peskin, Philadelphia College of Osteopathic MedicineFollow
• Frederick J. Goldstein, Philadelphia College of Osteopathic MedicineFollow
• Micky Bacchus, Philadelphia College of Osteopathic MedicineFollow
• Sarah Kizun, Philadelphia College of Osteopathic MedicineFollow
• Alivia Kurelowech, Philadelphia College of Osteopathic MedicineFollow
• Alexandra Loverdi, Philadelphia College of Osteopathic MedicineFollow
• Kruti Patel, Philadelphia College of Osteopathic MedicineFollow
• Neha Bhardwaj, Philadelphia College of Osteopathic MedicineFollow
• Tyler Kung, Philadelphia College of Osteopathic MedicineFollow
• Hiren Walia, Philadelphia College of Osteopathic MedicineFollow
• Rebecca Han, Philadelphia College of Osteopathic MedicineFollow
• Alexa Romanella, Philadelphia College of Osteopathic MedicineFollow
• Christie Okoye, Philadelphia College of Osteopathic MedicineFollow

Abstract

Introduction: Cannabis use among U.S. adults has increased substantially in recent years, and primary care physicians increasingly encounter patients using cannabis for chronic pain management. This case series describes two patients with chronic neuropathic pain participating in an observational study evaluating a dose-controlled oral tetrahydrocannabinol (THC): cannabidiol (CBD) formulation. Methods: Two participants completed a four-week program involving incremental oral administration of a 1:1 THC:CBD formulation. Pain intensity scores, medication use, and health-related quality of life (HRQoL) were assessed before and after the intervention. Results: Both participants reported reductions in pain intensity and decreased reliance on pre-study analgesic medications. Improvements were observed across multiple HRQoL domains, particularly in social functioning and perceived health. Conclusions: These cases suggest that an oral THC:CBD formulation may be associated with improvements in pain intensity and selected HRQoL measures in patients with chronic neuropathic pain. As an observational case series, these findings are exploratory and highlight considerations relevant to integrated primary care management of chronic pain.

Recommended Citation

Butera, Camryn; Robinson, Tytianna; Temucin, Samantha; McNulty, Jade; Pinto, Ryan; Rakoczy, Maya; Peskin, Jessica; Goldstein, Frederick J.; Bacchus, Micky; Kizun, Sarah; Kurelowech, Alivia; Loverdi, Alexandra; Patel, Kruti; Bhardwaj, Neha; Kung, Tyler; Walia, Hiren; Han, Rebecca; Romanella, Alexa; and Okoye, Christie (2026) "Integrating Oral THC:CBD Into Chronic Neuropathic Pain Management in Primary Care: A Two-Patient Observational Case Series," The Journal of Integrated Primary Care: Vol. 2: Iss. 4, Article 4.
Available at: https://digitalcommons.pcom.edu/jipc/vol2/iss4/4